What is it about?
Glaucoma (a group of conditions that damage the optic nerve and lead to blindness, often related to high pressure inside the eye) is a leading cause of preventable blindness worldwide. A new noninvasive therapy called MLT (Micropulse® Laser Trabeculoplasty) is meant to serve as an upgrade from the the previous SLT (Selective Laser Trabeculoplasty). We have shown for the first time that MLT may be a safer alternative to SLT while maintaining efficacy of treatment in a wider population of glaucoma patients.
Photo by v2osk on Unsplash
Why is it important?
Our findings show that MLT may be effective in a more diverse population than SLT and could be an improvement in safety over the older lasers.
Read the Original
This page is a summary of: Comparison of successful outcome predictors for MicroPulse® laser trabeculoplasty and selective laser trabeculoplasty at 6 months, Clinical Ophthalmology, June 2019, Dove Medical Press, DOI: 10.2147/opth.s205977.
You can read the full text:
The following have contributed to this page